Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

Inclusion Criteria: * Female patients \> 18 years and \< 65 years of age * Patients undergoing an aesthetic fat grafting procedure to the breast (breast augmentation) without a breast implant. * Patients must be able to provide written informed consent, understand and be willing to comply with study-related procedures and follow-up visits. * Patients must be non-smokers. * Patients with available/adequate harvest sites for fat grafting. * Anticipated harvested fat volume between 400 and 1400 cc * Anticipated fat injection volume 150-350 cc per breast * Patients must agree to maintain their weight (i.e. within 5%) by not making any major changes in their diet or lifestyle during the study. Exclusion Criteria: * Skin rash in the treatment area. * Patients who smoke or use nicotine products. * Patients with bleeding disorders or currently taking anticoagulants. * Patients with a history of trauma or surgery to the treatment area. * Patients with a history of breast cancer. * Active, chronic, or recurrent infection. * Compromised immune system (e.g. diabetes). * Hypersensitivity to analgesic agents. * Co-morbid conditions that could limit their ability to participate in the study or to comply with follow-up requirements. * Untreated drug and/or alcohol abuse. * Pregnant or breastfeeding. * Any issue that, at the discretion of the investigator, would contraindicate the patient's participation. * Patients who do not wish to have the study area (breast) photographed NOTE Please note that there is no remuneration for participation in this study.